According to a release, Bioventus Inc.’s third quarter 2023 financial results showed decreased net sales as well as a net loss resulting from its continuing operations.
Bioventus’ net sales were $120.8 million. This represents a 6.1% drop from the previous year. The company reported an $8.8-million net loss for continuing operations. Bioventus has also reported a adjusted earning before interest, taxes and depreciation of $21.7 millions and a loss of $0.12 per share for Class A common stocks.
“The enhanced visibility and predictability in our business, combined with our teams’ robust
